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For the purpose of predicting multiple sclerosis (MS) and neuromyelitis optica (NMO) relapses in Japanese population, we
evaluated the localization and age of each demyelinating attack. We retrospectively analyzed the 78 medical records of Japanese
MS and NMO patients. Then we identiﬁed 49 cases of relapsing-remitting-type patients and deﬁned each of 116 demyelinating
attacks.NMOhadanolderageatonsetthanMS,althoughtheinitialsymptomscannotpredicttheclinicalphenotypes.Only21.3%
of demyelinating attacks were localized in the cerebrum and 78.7% were optic-spinal lesions, although MS comprised 70% and
NMOcomprised30%ofthese78cases.Brainstemlesionhadarelativemalepredominancyandayoungageatattack.Ourﬁndings
showed that optic nerve and spinal cord lesions are the major and critical lesions in each attack of Japanese CNS demyelinating
diseases. There might be distinctive Japanese pathogenic features even in Western type MS.
1.Introduction
Multiple sclerosis (MS) and neuromyelitis optica (NMO) are
inﬂammatory demyelinating diseases of the central nervous
system (CNS). Although MS and NMO are characterized
by dissemination of lesions in space and dissemination in
time, it has not been able to predict when and where the
next relapse will appear. One of the possibilities that suggests
where the next relapse occurs is due to the clinical phenotype
of the CNS inﬂammatory demyelinating diseases in the
Japanese population. Japanese CNS demyelinating disease
has two major clinical phenotypes. One is NMO [1, 2]
which is characterized by lesions conﬁned to the optic nerve
and spinal cord, especially, longitudinally extensive spinal
cord lesions [3], positive aquaporin-4 (AQP4) autoantibody
seropositivity [4], and the astrocytic impairment associated
with the loss of AQP4 in the NMO lesions [5]. The other
is conventional Western type MS which is known to be
the same pathophysiology as MS in western countries and
frequently involves cerebral lesions [6]. Human leukocyte
antigen (HLA)-DR2 antigen is reported to associate with
MS both in Japan and western countries [7], whereas
DPB1∗0501 is associated with NMO in Asian population
[8, 9] .T h e r ei sac o n s e n s u st h a tN M Oc o m p r i s e sa b o u t
one-third or one-fourth of the Japanese CNS inﬂammatory
demyelinating diseases [10].
In this paper, for the purpose of predicting the lesions of
the demyelinating relapses, we evaluated the localization, sex
ratio, and age of each demyelinating attack, retrospectively.
As the results, we found that the attacks in optic nerve and
spinal cord accounted for about 80% of all MS and NMO
attacks, although NMO comprised only 30% of the Japanese
CNS inﬂammatory demyelinating diseases. Furthermore,
relapses in brainstem demonstrate unique characteristics
compared to other lesions. Thus, optic nerve and spinal
cord still play key roles in the Japanese CNS inﬂammatory
demyelinatingdiseasesofbothclinicalphenotypesofMSand
NMO.
2. Patients andMethods
2.1. Patients and Clinical Evaluation. We retrospectively
analyzed the medical records of Japanese patients admitted
to the Department of Neurology, Tokyo Metropolitan Neu-
rological Hospital, for the ﬁrst time between January 1992
and December 2001 and identiﬁed 78 patients diagnosed
as having MS and NMO [1, 11], and we analyzed their
baseline clinical characteristics. Then we followed them up2 ISRN Neurology
Table 1: Clinical characteristics and initial symptoms of MS and NMO patients.
Characteristics
Total of MS and
NMO MS NMO
n = 78 n = 55 n = 23
Sex
Male/female 21 (27%)/57 (73%) 15 (27%)/40 (73%) 6 (26%)/17 (74%)
Age at onset, y.o.
Mean ± SD 35.3 ± 13.6 32.5 ± 13.0a 41.9 ± 13.1a
Duration of disease, years
Mean ± SD 5.2 ± 7.0 6.0 ± 7.1 3.3 ± 6.3
EDSS
Mean ± SD 3.9 ± 2.5 3.9 ± 2.6 3.9 ± 2.2
Initial symptoms
Sensory disturbance 29% 24% 44%
Visual loss 26% 27% 22%
Double vision or vertigo 12% 15% 4%
Acute motor weakness 5% 5% 4%
Chronic motor weakness 5% 7% 0%
Sphincter disturbance 4% 2% 9%
Ataxia 1% 2% 0%
Consciousness disturbance 1% 2% 0%
Complex 17% 16% 17%
aMean age at onset of NMO patients was signiﬁcantly older than that of MS patients (P = 0.005). Student’s t-test was used for the statistical analysis.
and identiﬁed 49 cases of relapsing-remitting-type MS and
NMO. We deﬁned each of 116 clinical demyelinating attacks
that were conﬁrmed on MRI and optic neuritis diagnosed by
ophthalmologists. Thirty-three attacks occurred in 15 NMO
patients, and 83 attacks occurred in 34 MS patients.
2.2. Statistical Analysis. Student’s t-test or Welch’s t-test
was used for the statistical analysis of the age, duration of
disease, and EDSS. The sex ratio was analyzed using the
chi-square test or Fisher’s exact probability method (where
appropriate). All statistical analyses were performed using
a commercial software package (SPSS version 10.0J, SPSS
Japan Inc., Tokyo, Japan).
3. Results
3.1. Clinical Characteristics of Japanese CNS Demyelinating
Disease: Initial Symptoms Cannot Predict the Clinical Pheno-
types. Dividingthese78JapaneseCNSdemyelinatingdisease
patients into the two clinical phenotypes, NMO comprised
29.5% and MS comprised 70.5%, as previously reported
[10]. Table 1 shows the clinical characteristics of all the 78
Japanese CNS demyelinating disease patients. Age at onset
was signiﬁcantly older in NMO than in MS (P = 0.005).
Sex ratio was not diﬀerent between MS and NMO. Two
major initial symptoms were sensory disturbance and visual
loss both in MS and NMO. Other symptoms did not have
enough number to evidently discuss. Thus, in this analysis in
a general view, older age at onset is associated with the larger
possibility to be classiﬁed to NMO, although sex ratio and
the initial symptoms cannot predict the clinical phenotypes
in Japanese population.
3.2. Localization of Each Clinical Demyelinating Attack: Optic
NerveandSpinalCordWeretheMajorLesionsinJapaneseMS.
Localization of each of these 116 demyelinating attacks from
49 relapsing-remitting-type MS and NMO patients is shown
in Figure 1. Overall, 10.2% occurred in the cerebrum, 9.2%
the brainstem, 26.9% the optic nerve, 32.4% spinal cord,
10.2% comprised complex lesions excluding the cerebrum,
and 11.1% complex lesions including the cerebrum. Thus,
only 21.3% of demyelinating attacks were localized in the
cerebrum and 78.7% were optic-spinal lesions, although the
clinical phenotype showed that 70% occurred in MS and
30% in NMO.
3.3.BrainstemLesionHasaRelativeMalePredominancyanda
Young Age at Attack. The characteristics of each demyelinat-
ing localization were further investigated. Figure 2(a) shows
thathalfofthebrainstemlesionsoccurredinmales,although
therewasaremarkablefemalepredominancyforotherlesion
sites.
Furthermore, mean patient age at brainstem attack was
29.6 ± 6.0 year old and tended to be younger than that
for other lesions. Especially, mean patient age at brainstem
attack was signiﬁcantly younger than that at optic nerve
attack (42.5 ± 14.4 y.o.) or spinal cord attack (42.6 ± 13.6
y.o.) using Welch’s t-test (P < 0.05) (Figure 2(b)). Brain-
stem attacks occurred mostly between 20 and 40 years
old, although attacks at other localizations were widely
distributed from teenage to over 60 years old.ISRN Neurology 3
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Figure 1: Localization of each of 116 demyelinating attacks from
49 relapsing-remitting MS and NMO patients. 10.2% involved
the cerebrum, 9.2% the brainstem, 26.9% the optic nerve, 32.4%
the spinal cord, 10.2% involved complex lesions excluding the
cerebrum and, 11.1% complex lesions including the cerebrum.
Thus, only 21.3% of demyelinating attacks were localized in
cerebrum and 78.7% were optic-spinal lesions, although the clinical
phenotype showed that MS comprised 70% and NMO comprised
30%.
4. Discussion
This analysis is unique because we examined each patient
in detail characterizing each demyelinating attack, although
the initial symptoms of each MS patients have been widely
discussed. It was reported that visual loss is one of the most
common initial symptoms in Japan, although the incidence
of sensory and motor dysfunctions is larger than visual loss
in the western countries [12, 13]. There had been adequate
importance to assess the initial symptoms in the era of when
MRI was not invented and the clinical diagnosis of MS
was very diﬃcult. However, our study showed that initial
symptoms were no longer able to predict the relapses and
theclinicalphenotypesforeachJapaneseCNSdemyelinating
disease patients.
Our ﬁndings showed that optic nerve and spinal cord
lesions were the major and critical lesions in each attack of
Japanese CNS demyelinating diseases. Japanese MS has been
considered the same disease entity as prototypic western MS.
Moreover, recent revision of the McDonald Criteria for MS
in 2010 clearly deﬁned that once NMO and NMO spectrum
disorders have been excluded, Western type MS in Asian
populationisnotfundamentallydiﬀerentfromtypicalMSin
the Caucasian population [6]. However, our ﬁndings suggest
that there might be distinctive Japanese pathogenic features
even in MS, and, therefore, optic nerve attacks and spinal
cord attacks remain to have critical roles. It might be possible
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Figure 2: (a) Sex ratio of each localization of MS attacks. Half
of the brainstem lesions occurred in males, although there was a
remarkable female predominancy for other lesion sites. (b) Age at
attack for each localization of MS attacks. Mean age at brainstem
attack was 29.6 ± 6.0 years old and is signiﬁcantly younger than
themeanageatopticnerv eattack(42.5± 14.4y.o.)andspinalcord
attack (42.6 ± 13.6 y.o.) using Welch’s t-test (P < 0.05). Regarding
other lesions, mean patient age at attacks involving the cerebrum
was 42.3 ± 13.5 y.o., and the mean age at the development of
complex lesions was 38.7 ± 10.9 y.o. Boxes represent values from
the 25th to the 75th percentiles, inner lines represent the median,
and whiskers show the minimal and maximal values.
that attacks causing visual loss or transverse myelitis are
severe and require hospital care; therefore, the number of
optic and spinal attacks was increased in this study. However,
we think that this hypothesis is inaccurate because the mean
EDSS did not diﬀer between NMO and MS.
Brainstem lesions demonstrate striking diﬀerences in sex
ratio and age at relapse compared to other lesions and
were frequently seen in young adult males. Although sex
diﬀerences in the pathomechanism for MS are unsolved
problems, this feature would be explained by hormonal and
genetic studies [14].
Interferon beta-1b (IFNB-1b) was reported to be eﬀec-
tive for not only patients in Western countries but also
Japanese relapsing-remitting MS patients according to a
randomized, double-blind clinical study [15]. Conversely,
IFNB-1b treatment for NMO could increase the relapse
rate of NMO or cause severe side eﬀects such as severe
skin ulcers at injection sites requiring surgical repair; thus,
it should not be administered to NMO patients [16]. We
suspect that certain Japanese MS patients whose optic nerve
attacks and spinal cord attacks have critical roles might play4 ISRN Neurology
an intermediate role between MS and NMO and that the
treatment adequate for those intermediate patients might be
notonlyimmunomodulatingtherapyincludingIFNB-1bbut
also immunosuppressive therapy including prednisolone,
immunosuppressant, monoclonal antibodies, and biologics.
5. Conclusions
Our ﬁndings showed that optic nerve and spinal cord lesions
were the major and critical lesions in each attack of Japanese
MS. There might be the Japanese distinctive pathogenic
features even in Western type MS, and, therefore, optic nerve
attacks and spinal cord attacks remain to have critical roles
in the Japanese population. We suspect that certain Japanese
MSpatientsmightplayanintermediaterolebetweenMSand
NMOandthatthetreatmentadequateforthoseintermediate
patients might be not only immunomodulating therapy but
also immunosuppressive therapy.
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